Inactive

AMENDMENT No.: 02 from January 19, 2022. QUOTATION DUE DATE: 09:00am Eastern Time on January 24, 2022 (Changed) This amendment No.: 02 is to respond to formal questions submitted in response to the so... AMENDMENT No.: 02 from January 19, 2022. QUOTATION DUE DATE: 09:00am Eastern Time on January 24, 2022 (Changed) This amendment No.: 02 is to respond to formal questions submitted in response to the solicitation. This amendment No.: 02 is attached in full (D Mod_2_75N95022Q00080) END OF AMENDMENT No.: 02 from January 19, 2022. AMENDMENT No.: 01 from January 19, 2022. QUOTATION DUE DATE: 09:00am Eastern Time on January 20, 2022 (Unchanged) This amendment No.: 01 is to respond to formal questions submitted in response to the solicitation. This amendment No.: 01 is attached in full (D Mod_1_75N95022Q00080) END OF AMENDMENT No.: 01 from January 19, 2022. (i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is 75N95022Q00080 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures; and FAR Part 12—Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) Number 2022-03, with effective date January 1, 2022. (iv) The associated NAICS code 541380 Testing Laboratories and the small business size standard $16.5M. There are no set-aside restrictions for this requirement. DESCRIPTION (v) The National Institutes of Health (NIH) is the nation’s leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people’s health and save lives. National Center for Advancing Translational Sciences (NCATS) is one of 27 Institutes and Centers at the NIH and its mission is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. The Division of Preclinical Innovation (DPI) within NCATS plans, conducts and uses both internal and contract resources to advance collaborative research projects across the preclinical phases of the translational science spectrum. The kinase LATS1 is of interest to NCATS in several different disease indications. Currently, there is no x-ray structure of LATS1. In order to further the current development of small molecule inhibitors of LATS1, a high-quality x-ray structure of the protein, both alone and in complex with small molecule inhibitors is required by NCATS. The X-ray structure will provide in depth structural information about the biophysical conformation of the protein. This structural information can be used to better design small molecule inhibitors of the protein. (vi) The NCATS DPI requires three (3) x-ray structures of the LATS1, both alone and in complex with two (2) small molecule inhibitor, in order to further the current development of small molecule inhibitors of LATS1, as per the specific requirements provided in the attached STATEMENT OF WORK. (vii) The Government anticipates award of a firm fixed-price purchase order for this requirement, and the anticipated period of performance is January 21, 2022 through January 20, 2023 (12-months). TERMS AND CONDITIONS, PROVISIONS, AND REPRESENTATIONS (viii) The provision at FAR clause 52.212-1, Instructions to Offerors – Commercial Products and Commercial Services (Nov 2021), applies to this acquisition. (ix) The Quoters are to include a completed copy of the attached provision at FAR 52.212-3, Offeror Representations and Certifications- Commercial Products and Commercial Services (Nov 2021), with its quote. The Offeror shall complete only paragraph (b) of the FAR 52.212-3 provision if the Offeror has completed the annual representations and certification electronically in the System for Award Management (SAM) accessed through https://www.sam.gov. If the Offeror has not completed the annual representations and certifications electronically, the Offeror shall complete only paragraphs (c) through (v) of the FAR 52.212-3 provision. If applicable, the following FAR Provision Representations and Certifications must be completed, signed, and returned by the quoters with its quote pursuant to FAR 4.2103 Procedures: FAR 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Nov 2021) – Attached. FAR 52.204-26 Covered Telecommunications Equipment or Services -Representation (Oct 2020) – Attached. (x) The clause at FAR 52.212-4, Contract Terms and Conditions—Commercial Products and Commercial Services (Nov 2021) applies to this acquisition. Addendum to this FAR clause applies to this acquisition and is attached. The additional contract terms and conditions are as follows. FAR 52.212-4(g), Invoice, is supplemented by: NIH Invoice and Payment Instructions (Rev. Feb 2021) - Attached FAR 52.212-4(u), NIH considers unenforceable any provision in your mass-market commercial sales and/or license agreement terms and conditions that are inapplicable to Federal procurement contracts, including, without limitation, any term or condition that: (1) Contravenes a right granted NIH under U.S. copyright law (e.g., fair use, right to archive, copying for interlibrary loan), (2) Violates the Federal Acquisition Regulation or other Federal law (e.g., Antideficiency Act, Principles of Federal Appropriations Law), (3) Departs from reasonable consumer expectations, or (4) Violates fundamental public policy. Please be advised that the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) is a Federal agency. Your mass-market commercial sales and/or license agreement terms and conditions may include provisions that are customarily found in the commercial sector but which are not enforceable under a contract with a Federal agency. By submission of a quotation/proposal and execution of the order/contract, the Contractor hereby accepts and agrees to the terms and conditions of the order/contract. (xi) The clause at FAR 52.212-5 Contract Terms and Conditions—Commercial Products and Commercial Services (Jan 2022) applies to this acquisition and is attached in full text. (xii) The following additional contract requirement(s) or terms and conditions as determined by the contracting officer are necessary for this acquisition and consistent with customary commercial practices. The provision at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb 1998), applies to this acquisition. This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html (End of provision) The following provisions apply to this acquisition and are incorporated by reference: FAR 52.204-7, System for Award Management (Oct 2018) FAR 52.204-16, Commercial and Government Entity Code Reporting (Aug 2020) FAR 52.212-1, Instructions to Offerors—Commercial Products and Commercial Services (Nov 2021) FAR 52.225-4, Buy American-Free Trade Agreements-Israel Trade Act Certificate (Feb 2021) HHSAR 352.239-73 Electronic Information and Technology Accessibility Notice (December 18, 2015) The clause at FAR 52.252-2, Clauses Incorporated by Reference (Feb 1998), applies to this acquisition. This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html (End of clause) The following clauses apply to this acquisition and are incorporated by reference: FAR 52.204-13, System for Award Management Maintenance (Oct 2018) FAR 52.204-18, Commercial and Government Entity Code Maintenance (Aug 2020) FAR 52.212-4 Contract Terms and Conditions—Commercial Products and Commercial Services (Nov 2021) FAR 52.227-14, Rights in Data-General (May 2014) HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015) HHSAR 352.224-71, Confidential Information (December 18, 2015) HHSAR 352.224-71 (c)(2)(i) The publication or dissemination of the following types of information are restricted under this contract: 1) the compound structures provided by the Government and results of the analysis. HHSAR 352.224-71 (c)(2)(ii) The reason for restricting the types of information identified in subparagraph (i) is: 1) The analysis results are commercial confidential information and may be used in the development of a future commercial treatment HHSAR 352.239-74 Electronic and Information Technology Accessibility (December 18, 2015) (xiii) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. EVALUATION (xiv) The Government may perform a comparative evaluation of responses in accordance with FAR 13.106-2(b) to select the contractor that is best suited and provides the best value, considering the evaluation factors in this solicitation. The evaluation will compare: (a) Technical capability of the item offered to meet the Government requirement in accordance with the salient characteristics specified in the Statement of Work; (b) Price; and (c) Past Performance as defined under FAR 13.106-2(b)(3). If only one quotation is received it will be evaluated on the preceding. The government reserves the right to select a response that provides benefit to the government that exceeds the minimum; the government is not required to select a response that exceeds the minimum; responses may exceed the requirements; each response must meet the solicitation requirement statement at a minimum; and the government is not requesting or accepting alternate proposal(s). SUBMISSION INSTRUCTIONS (xv) Responses to this solicitation must include sufficient information to establish the interested parties’ bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s), product description, and any other information or factors that may be considered in the award decision. Such factors may include: past performance, special features required for effective program performance, trade-in considerations, probable life of the item selected as compared with that of a comparable item, warranty considerations, maintenance availability, and environmental and energy efficiency considerations. Responses to this solicitation must include clear and convincing evidence of the offeror’s capability of fulfilling the requirement as it relates to the technical evaluation criteria. The Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency. All responses must be received by 9:00 a.m., Eastern Time, on January 20, 2022 and reference Solicitation Number 75N95022Q00080. Responses must be submitted by email to Renato Gomes at renato.gomes@nih.gov. (xvi) The name and telephone number of the individual to contact for information regarding the solicitation: Renato Gomes Contract Specialist Phone: (301) 451-2596 Email: renato.gomes@nih.gov ATTACHMENTS (xvi) Attachments: Statement of Work (SOW) FAR 52.204-24, Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Nov 2021) FAR 52.204-26, Covered Telecommunications Equipment or Services-Representation (Oct 2020) FAR 52.212-3, Offeror Representations and Certifications—Commercial Products and Commercial Services (Nov 2021) Addendum to FAR 52.212-4 Terms and Conditions – Commercial Items FAR 52.212-5, Contract Terms and Conditions—Commercial Products and Commercial Services (Jan 2022) FAR 52.225-4, Buy American-Free Trade Agreements-Israel Trade Act Certificate (Feb 2021) NIH Invoice and Payment Provisions (Rev. February 10, 2021)